Emergence of polymyxin B-resistant Acinetobacter baumannii in hospitals in Rio de Janeiro

Genteluci, Gabrielle Limeira; Gomes, Daniela Betzler Cardoso; Souza, Maria José de; Carvalho, Karyne Rangel; Villas-Bôas, Maria Helena Simões

doi:10.5935/1676-2444.20160021

Cited by 9 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From 92 samples, 85 presented MIC values ranging from 4 to 64 μ g/mL and were characterized as resistant to polymyxin B. Differently from Genteluci et al [ 28 ], a study which analyzed the activities of the polymyxins B and E against 100 clinical isolates of P. aeruginosa ( n = 65) and A. baumannii ( n = 35) collected from two public hospitals from Recife-PE, Brazil, demonstrated that all isolates were sensitive to both polymyxins [ 2 ].…”

Section: Resultsmentioning

confidence: 98%

“…Genteluci et al [ 28 ] have reported an alarming frequency of polymyxin B-resistant strains of A. baumannii in clinical isolates from a tertiary hospital in Rio de Janeiro, Brazil. From 92 samples, 85 presented MIC values ranging from 4 to 64 μ g/mL and were characterized as resistant to polymyxin B.…”

Section: Resultsmentioning

confidence: 99%

“…and P. aeruginosa isolates compared to the present study. The presence of different percentages of polymyxin-resistant strains in different parts of the world is related to the public health characteristics, number of inhabitants, sanitation, and economic development, those being considered determinant factors in the health-disease process [ 28 – 30 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

“…Studies developed in Brazil between 2009 and 2017 reported that drugs such as the polymyxins should be the last therapeutic resource against multidrug-resistant strains of P. aeruginosa and Acinetobacter spp. Besides, pan-resistant strains of these same species have been found in clinical isolates from patients admitted in intensive care units (ICUs) in Brazilian hospitals [3,28,29].…”

Section: Susceptibility Profile To Polymyxin Bmentioning

confidence: 99%

“…and P. aeruginosa isolates compared to the present study. e presence of different percentages of polymyxinresistant strains in different parts of the world is related to the public health characteristics, number of inhabitants, sanitation, and economic development, those being considered determinant factors in the health-disease process [28][29][30]32]. Clinical isolates of P. aeruginosa which presented an intermediate susceptibility to polymyxin B were present in tracheal secretion samples, whereas resistant isolates were found in urine (3/5), catheter tip (1/5), and ulcer secretion (1/5).…”

Section: Susceptibility Profile To Polymyxin Bmentioning

confidence: 99%

See 4 more Smart Citations

Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa

Júnior

Silva

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The present study aimed to characterize the susceptibility profile of Pseudomonas aeruginosa and Acinetobacter spp. clinical isolates to polymyxin B in a public hospital in Recife-PE, Brazil, between the years of 2018 and 2019, as well as to search for the presence of the mcr-1 gene and evaluate the interaction between polymyxin B and usnic acid against these isolates. The strains were identified using the BD Phoenix™ automated system and the agar-spot test was used to determine the susceptibility profile to polymyxin B. The minimum inhibitory concentrations (MICs) of usnic acid and polymyxin B were determined through the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). Subsequently, Polymerase Chain Reaction (PCR) was performed to detect the mcr-1 gene in the isolates. The interaction between usnic acid and polymyxin B was evaluated by the Checkerboard assay. Among 34 isolates of P. aeruginosa, 26.5% (9/34) were positive for the polymyxin B agar-spot test, and 11.8% (4/34) presented an intermediate susceptibility (MIC = 4 μg/mL), while 14.7% (5/34) presented antimicrobial resistance with MIC values ranging from 8 to 32 μg/mL. Among 38 isolates of Acinetobacter spp., 13.2% (5/38) were positive for the polymyxin B agar-spot test and all of them were resistant to polymyxin B with a MIC value > 32 μg/mL. The mcr-1 gene was not detected in the clinical isolates. Regarding usnic acid, it presented a moderate antibacterial activity against two P. aeruginosa isolates (MIC = 250 μg/mL) and no activity was detected against the others. A synergistic effect between usnic acid and polymyxin B was observed against three clinical isolates of P. aeruginosa which were resistant to polymyxin B (FICI ≤ 0.5). Therefore, it was possible to observe that usnic acid is a promising candidate to be used in combination with polymyxin B against infections caused by resistant P. aeruginosa.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%